Fig. 3: The phenotypic heterogeneity of myeloid cells.

a t-SNE plot showing a total of 15,366 myeloid cells, separated into 28 subtypes. b Cells are colored according to tissue origins (top) and treatment status (bottom). c Left, heat map showing normalized expression (z-score) of function-associated genes in TAM subsets. Black boxes highlight the prominent patterns defining TAM subtypes. Right, bar plot showing the tissue origin and treatment status of each TAM subtype. d Bottom, based on the annotation and classification above, bar plots depicting cell numbers of each cell type in tumors with or without PC treatment are shown. Top, pie charts showing the proportions of different TAM subsets within different tissues (the primary CRC, liver metastases). e Boxplot comparing the frequency of immature TAMs in treated and treatment-naïve patients both in primary CRC and liver metastases. Wilcoxon rank-sum test was used for statistical analysis. f Overall survival curves of TCGA COAD patients (Cox regression). We identified an M11 TAM signature composed of 26 genes that showed significantly increased expression in M11 vs other TAM clusters. g Immunofluorescence analysis showing M11 (S100B⁺MMP122⁺CD68⁺) cell numbers in tumors treated with or without PC. h Boxplot showing the levels of M11 signature in pretreated samples from the human colorectal cancer dataset GSE12246, adjuvant chemotherapy⁸⁶.